Abstract
Between January 1981 and December 1985, 122 patients with non-seminomatous germ cell tumours (NSGT) were seen at a regional referral centre. Of these, a total of 98 patients received chemotherapy for metastatic disease. Treatment was given within collaborative EORTC Urology group studies, all of which involved cis-platin-containing schedules. Ninety patients had tumours of testicular origin, and their 2 year actuarial survival rate is 91%; 8 had tumours of extragonadal origin and their 2 year actuarial survival is 25%. Patients with testicular tumours were subdivided by volume of metastatic disease using the recommendations of the Testicular Cancer Subgroup of the MRC Urological Cancer Working Party and survival was significantly worse in the group with very large volume metastatic disease (VLVM, 57%) compared with the groups with large volume metastases (LVM, 100%) and small volume metastases (SVM, 98%). There were 31 patients with Stage I disease at presentation; of these 6 were treated by prophylactic abdominal radiotherapy and 25 were managed by a policy of surveillance only. Seven of these Stage I patients (23%) relapsed with metastatic disease (median 8 months); all have been successfully treated with chemotherapy. These data confirm that the majority of patients now presenting with metastatic NSGCT are curable with chemotherapy, but that a small proportion with very large volume metastases or extragonadal tumours require alternative chemotherapy schedules.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Einhorn L. H. Have new aggressive chemotherapy regimens improved results in advanced germ cell tumors? Eur J Cancer Clin Oncol. 1986 Nov;22(11):1289–1293. doi: 10.1016/0277-5379(86)90135-5. [DOI] [PubMed] [Google Scholar]
- Freedman L. S., Parkinson M. C., Jones W. G., Oliver R. T., Peckham M. J., Read G., Newlands E. S., Williams C. J. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987 Aug 8;2(8554):294–298. doi: 10.1016/s0140-6736(87)90889-0. [DOI] [PubMed] [Google Scholar]
- Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
- Hainsworth J. D., Einhorn L. H., Williams S. D., Stewart M., Greco F. A. Advanced extragonadal germ-cell tumors. Successful treatment with combination chemotherapy. Ann Intern Med. 1982 Jul;97(1):7–11. doi: 10.7326/0003-4819-97-1-7. [DOI] [PubMed] [Google Scholar]
- Newlands E. S., Bagshawe K. D., Begent R. H., Rustin G. J., Crawford S. M., Holden L. Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol. 1986 Jun;58(3):307–314. doi: 10.1111/j.1464-410x.1986.tb09061.x. [DOI] [PubMed] [Google Scholar]
- Peckham M. J., Barrett A., Horwich A., Hendry W. F. Orchiectomy alone for Stage I testicular non-seminoma. A progress report on the Royal Marsden Hospital study. Br J Urol. 1983 Dec;55(6):754–759. doi: 10.1111/j.1464-410x.1983.tb03420.x. [DOI] [PubMed] [Google Scholar]
- Stoter G., Sleyfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., van Oosterom A. T., Vendrik C. P., Spaander P., de Pauw M., Sylvester R. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1986 Aug;4(8):1199–1206. doi: 10.1200/JCO.1986.4.8.1199. [DOI] [PubMed] [Google Scholar]
- Wheeler B. M., Loehrer P. J., Williams S. D., Einhorn L. H. Ifosfamide in refractory male germ cell tumors. J Clin Oncol. 1986 Jan;4(1):28–34. doi: 10.1200/JCO.1986.4.1.28. [DOI] [PubMed] [Google Scholar]